Exploring the relationship between forced maximal flow at functional residual capacity and parameters of forced expiration from raised lung volume in healthy infants
Abstract:The raised volume rapid thoraco-abdominal compression technique (RVRTC) is being increasingly used to assess airway function in infants, but as yet no consensus exists regarding the equipment, methods, or analysis of recorded data. The aim of this study was to explore the relationship between maximal flow at functional residual capacity (V'(maxFRC)) and parameters derived from raised lung volumes, and to address analytical aspects of the latter technique in an attempt to assist with future standardization init… Show more
“…Assessing airway patency by means of the RVRTC technique is promising but has not yet proved to be beneficial over the RTC technique. 19 Furthermore, RVRTC technique is not standardised since it lacks consensus. 16 20 Although the RTC technique is well accepted and standardised, several disadvantages have become apparent.…”
Background: Controversy remains regarding the effectiveness of bronchodilators in wheezy infants. Aims: To assess the effect of inhaled β 2 agonists on lung function in infants with malacia or recurrent wheeze, and to determine whether a negative effect of β 2 agonists on forced expiratory flow (V′ maxFRC ) is more pronounced in infants with airway malacia, compared to infants with wheeze. Methods: We retrospectively analysed lung function data of 27 infants: eight with malacia, 19 with recurrent wheeze. Mean (SD) age was 51 (18) weeks. Mean V′ maxFRC (in Z score) was assessed before and after inhalation of β 2 agonists. Results: Baseline V′ maxFRC was below reference values for both groups. Following inhalation of β 2 agonists the mean (95% CI) change in mean V′ maxFRC in Z scores was −0.10 (−0.26 to 0.05) and −0.33 (−0.55 to −0.11) for the malacia and wheeze group, respectively. Conclusions: In infants with wheeze, inhaled β 2 agonists caused a significant reduction in mean V′ max -
“…Assessing airway patency by means of the RVRTC technique is promising but has not yet proved to be beneficial over the RTC technique. 19 Furthermore, RVRTC technique is not standardised since it lacks consensus. 16 20 Although the RTC technique is well accepted and standardised, several disadvantages have become apparent.…”
Background: Controversy remains regarding the effectiveness of bronchodilators in wheezy infants. Aims: To assess the effect of inhaled β 2 agonists on lung function in infants with malacia or recurrent wheeze, and to determine whether a negative effect of β 2 agonists on forced expiratory flow (V′ maxFRC ) is more pronounced in infants with airway malacia, compared to infants with wheeze. Methods: We retrospectively analysed lung function data of 27 infants: eight with malacia, 19 with recurrent wheeze. Mean (SD) age was 51 (18) weeks. Mean V′ maxFRC (in Z score) was assessed before and after inhalation of β 2 agonists. Results: Baseline V′ maxFRC was below reference values for both groups. Following inhalation of β 2 agonists the mean (95% CI) change in mean V′ maxFRC in Z scores was −0.10 (−0.26 to 0.05) and −0.33 (−0.55 to −0.11) for the malacia and wheeze group, respectively. Conclusions: In infants with wheeze, inhaled β 2 agonists caused a significant reduction in mean V′ max -
“…Tidal breathing parameters, including respiratory rate (RR), tidal volume (VT), minute ventilation (MV), and time to TPTEF as TPTEF:TE were calculated during tidal breathing. FEV0.4 was reported from the "best" flow/volume curve (defined as the technically acceptable manoeuvre with the highest sum of forced vital capacity and FEV0.4) [16,22,24]. Results were expressed both in absolute terms and as SD scores, based on measurements obtained in the healthy infants.…”
Section: Calculation Of Resultsmentioning
confidence: 99%
“…Manoeuvres were repeated until at least two acceptable and repeatable flow/volume curves were obtained [16,22].…”
Section: Measurements Of Lung Functionmentioning
confidence: 99%
“…Measurements of FEV0.4 were performed as described in detail previously using the raised volume technique at a lung inflation pressure of 3 kPa [16,22]. Manoeuvres were repeated until at least two acceptable and repeatable flow/volume curves were obtained [16,22].…”
Simple methods are needed to assess lung function in infants with cystic fibrosis (CF). This study determined the relationship between simple measurements obtained from tidal breathing with those from more complicated forced expiratory manoeuvres.Healthy infants and infants with CF were recruited from two maternity units and five specialist CF hospitals, respectively. Respiratory rate, tidal volume, minute ventilation and the tidal breathing ratio (TPTEF:TE) were measured in sedated infants and compared with forced expiratory volume in 0.4 seconds (FEV0.4) measured by the raised volume technique.Altogether, 95 healthy infants and 47 infants with CF of similar age, sex, ethnicity and proportion exposed to maternal smoking were recruited. There was no difference in TPTEF:TE and tidal volume between healthy infants and those with CF. Minute ventilation was significantly greater in infants with CF due to a mean (95% confidence interval) increase in respiratory rate of 5.8 (3.2-8.4) min -1 . Thirteen (28%) infants with CF had a respiratory rate elevated by w2 SD. However, no association between respiratory rate and FEV0.4 could be identified.Tidal breathing ratio was not useful in identifying diminished airway function in infants with cystic fibrosis. An elevated respiratory rate may be due in part to ventilation heterogeneity but is poorly predictive of diminished airway function measured by forced expiration. Eur Respir J 2003; 22: 761-766.
“…Success in obtaining technically acceptable data depends on experience [54]. Mean within-test, withinsubject coefficients of variation range from 3.4% to 4.1% for forced expired volumes (FEV) and from 7.8% to 8.9% for forced expiratory flows (FEF) [55,56]. Measurements made 1 month apart in 41 infants with CF provide evidence for good reproducibility, with a mean intraclass correlation of 0.85 and o0.9 for FEF and FEV, respectively [54].…”
Cystic fibrosis (CF) lung disease starts early in life and progresses even in the absence of clinical symptoms. Therefore, sensitive outcome measures to quantify and track these early abnormalities in infants and young children are needed; both for clinical care and interventional trials. Currently, the efficacy of most therapeutic interventions in CF has not been tested in children under the age of 6 years and drug development programmes have focused on assessing safety rather than efficacy in this age group. This article summarises the current status for outcome measures that can be utilised in clinical trials in infants and children with CF. Two methodologies are specifically highlighted in this review; chest computed tomography to assess structural damage of the lung and multiple breath washout as a technique to quantify ventilation inhomogeneity. While not all questions regarding the utility of these outcome measures in infants and young children have been resolved, significant advances have been made and it now appears feasible to design and conduct adequately powered efficacy studies in this age group. This could be a crucial step to further improve outcomes in CF patients as initiating effective treatment early is considered essential to prevent permanent lung damage. @ERSpublications Crucial to CF outcome is early effective treatment, hence intervention studies in infants and preschool children are a must
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.